Spyre Therapeutics第一季度每股收益$（0.62）击败$（0.84）估计

Spyre Therapeutics (NASDAQ: SYRE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.84) by 26.19 percent. This is a 48.33 percent increase over losses of $(1.20) per share from the same period last year.